Cargando…
Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate vaccine confers protection against SARS-CoV-2
With the COVID-19 pandemic globally, the ongoing threat of new challenges of mucosal infections was once again reminded human beings. Hence, access to the next-generation vaccine to elicit mucosal immunity is required to reduce virus shedding. SARS-CoV-2 retains a unique polybasic cleavage motif in...
Autores principales: | Abdoli, Mohsen, Shafaati, Maryam, Ghamsari, Ladan Kazem, Abdoli, Asghar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270963/ https://www.ncbi.nlm.nih.gov/pubmed/35820511 http://dx.doi.org/10.1016/j.virusres.2022.198857 |
Ejemplares similares
-
SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies
por: Salimi-Jeda, Ali, et al.
Publicado: (2021) -
Reducing transmission of SARS-CoV-2 with intranasal prophylaxis
por: Boiardi, Federico, et al.
Publicado: (2020) -
Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable
por: Adashi, Eli Y., et al.
Publicado: (2022) -
An intranasal ASO therapeutic targeting SARS-CoV-2
por: Zhu, Chi, et al.
Publicado: (2022) -
Regression of Lung Cancer in Mice by Intranasal Administration of SARS-CoV-2 Spike S1
por: Sheinin, Monica, et al.
Publicado: (2022)